Global Blood Therapeutics Inc., of South San Francisco, reported results from its ongoing phase I/II GBT440-001 study in sickle cell disease at the European Hematology Association meeting in Copenhagen, Denmark, including a presentation of 90-day data from a cohort of patients taking 700 mg/day of GBT440, showing a durable reduction in hemolysis from baseline, as evidence by a rapid and sustained reduction in bilirubin starting as early as day four.